1. Home
  2. CCCC vs DBCA Comparison

CCCC vs DBCA Comparison

Compare CCCC & DBCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo C4 Therapeutics Inc.

CCCC

C4 Therapeutics Inc.

HOLD

Current Price

$3.88

Market Cap

404.7M

Sector

Health Care

ML Signal

HOLD

DBCA

D. Boral Acquisition I Corp. Class A Ordinary Shares

N/A

Current Price

$10.00

Market Cap

432.3M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
CCCC
DBCA
Founded
2015
2025
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Blank Checks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
404.7M
432.3M
IPO Year
2020
2025

Fundamental Metrics

Financial Performance
Metric
CCCC
DBCA
Price
$3.88
$10.00
Analyst Decision
Strong Buy
Analyst Count
6
0
Target Price
$12.20
N/A
AVG Volume (30 Days)
2.3M
80.2K
Earning Date
05-06-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
16.45
N/A
EPS
N/A
N/A
Revenue
$35,947,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
1.02
N/A
52 Week Low
$1.69
$9.83
52 Week High
$5.17
$10.07

Technical Indicators

Market Signals
Indicator
CCCC
DBCA
Relative Strength Index (RSI) 51.85 56.77
Support Level $3.40 $9.98
Resistance Level $4.49 $10.05
Average True Range (ATR) 0.25 0.01
MACD 0.01 -0.00
Stochastic Oscillator 51.70 60.00

Price Performance

Historical Comparison
CCCC
DBCA

About CCCC C4 Therapeutics Inc.

C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.

About DBCA D. Boral Acquisition I Corp. Class A Ordinary Shares

D Boral Acquisition I Corp is a blank check company. It is formed as a BVI business company and formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.

Share on Social Networks: